Double Blind Placebo Controlled Dose Ranging Study for the Assessment of Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single Ascending and Multiple Oral Doses of GLPG0555 in Healthy Subjects.
Latest Information Update: 20 Aug 2023
At a glance
- Drugs GLPG 0555 (Primary)
- Indications Osteoarthritis
- Focus Adverse reactions
- 20 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 20 May 2010 Actual end date (May 2010) added as reported by ClinicalTrials.gov.
- 11 Dec 2009 New trial record